Patient Registry of Blind Subjects With Sleep-related Problems

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorVanda Pharmaceuticals

About this trial

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.

Subjects must be blind.

Subjects must have some self-described problem with sleep or daytime sleepiness.

Disqualifiers

None

Trial population

General population of blind individuals

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • Data collection on blindness and sleep problems

    Other intervention

    Data related to degree of vision impairment and sleep problems is collected through a phone or web survey

Treatment groups

10,000 Participants
are divided into 1 treatment group
Group A: Blind with sleep problems1 intervention

Trial outcomes

Primary outcomes

1

Number of blind participants

Time frame
ongoing

Secondary outcomes

1

Sleep/wake disruptions

Time frame
ongoing

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.